1. Home
  2. BATRA vs IBRX Comparison

BATRA vs IBRX Comparison

Compare BATRA & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atlanta Braves Holdings Inc. Series A

BATRA

Atlanta Braves Holdings Inc. Series A

HOLD

Current Price

$43.37

Market Cap

2.7B

Sector

Industrials

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$2.38

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BATRA
IBRX
Founded
1991
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BATRA
IBRX
Price
$43.37
$2.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$58.00
$9.71
AVG Volume (30 Days)
54.4K
11.5M
Earning Date
11-05-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$723,307,000.00
$82,555,000.00
Revenue This Year
$12.40
$667.18
Revenue Next Year
$6.78
$88.32
P/E Ratio
N/A
N/A
Revenue Growth
6.62
1025.95
52 Week Low
$38.67
$1.83
52 Week High
$50.50
$4.27

Technical Indicators

Market Signals
Indicator
BATRA
IBRX
Relative Strength Index (RSI) 59.51 56.50
Support Level $42.06 $2.17
Resistance Level $42.85 $2.40
Average True Range (ATR) 0.64 0.15
MACD 0.13 0.03
Stochastic Oscillator 82.73 72.22

Price Performance

Historical Comparison
BATRA
IBRX

About BATRA Atlanta Braves Holdings Inc. Series A

Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: